Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Kyowa Kirin Drug Patent Portfolio

Kyowa Kirin owns 1 orange book drug protected by 4 US patents Given below is the list of Kyowa Kirin's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7727993 Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy 28 Jan, 2028
Active
US8318201 Method of stabilizing diarylvinylene compound 05 Sep, 2027
Active
US7541363 Microcrystal 13 Nov, 2024
Active
US7727994 Methods of treating patients suffering from movement disorders 18 Jan, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Kyowa Kirin.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8318201
Patent Term Extension Certificate
Critical
17 Oct, 2023 US7727993
Notice of Final Determination -Eligible 18 Jul, 2023 US7727993
FDA Final Eligibility Letter
Critical
13 Jul, 2023 US7727994
FDA Final Eligibility Letter
Critical
13 Jul, 2023 US7727993
Interim Patent Term Extension Granted
Critical
22 Feb, 2023 US7727993
Withdrawal of Application for PTE
Critical
22 Feb, 2023 US7727994
transaction for FDA Determination of Regulatory Review Period 07 Nov, 2022 US7727993
transaction for FDA Determination of Regulatory Review Period 07 Nov, 2022 US7727994
Interim Patent Term Extension Granted
Critical
21 Sep, 2022 US7727994
Interim Patent Term Extension Granted
Critical
21 Sep, 2022 US7727993
Payment of Maintenance Fee, 12th Year, Large Entity 17 Nov, 2021 US7727993
Payment of Maintenance Fee, 12th Year, Large Entity 17 Nov, 2021 US7727994
Second letter to regulating agency to determine regulatory review period 19 Feb, 2021 US7727993
Second letter to regulating agency to determine regulatory review period 19 Feb, 2021 US7727994


Kyowa Kirin's Family Patents

Kyowa Kirin drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 17.2% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Kyowa Kirin Drug List

Given below is the complete list of Kyowa Kirin's drugs and the patents protecting them.


1. Nourianz

Nourianz is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7727993 Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy 28 Jan, 2028
(3 years from now)
Active
US8318201 Method of stabilizing diarylvinylene compound 05 Sep, 2027
(2 years from now)
Active
US7541363 Microcrystal 13 Nov, 2024
(25 days from now)
Active
US7727994 Methods of treating patients suffering from movement disorders 18 Jan, 2023
(1 year, 8 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nourianz's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List